A randomized trial of punctuated antiretroviral therapy in Ugandan HIV-seropositive adults with pulmonary tuberculosis and CD4+ T-cell counts of ≥350 cells/μL

Journal of Infectious Diseases

Volumn 204, Issue 6, 2011, Pages 884-892

  Nanteza, M W ^a   Mayanja Kizza, H ^a   Charlebois, E ^c   Srikantiah, P ^c   Lin, R ^c   Mupere, E ^a,b   Mugyenyi, P ^d   Boom, W H ^e   Mugerwa, R D ^a,b   Havlir, D V ^c   Whalen, Christopher C ^f  

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b MAKERERE UNIVERSITY   (Uganda)

^c UNIVERSITY OF CALIFORNIA   (United States)

^d Oint Clinical Research Center   (Uganda)

^e CASE WESTERN RESERVE UNIVERSITY SCHOOL OF MEDICINE   (United States)

^f UNIVERSITY OF GEORGIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ABACAVIR PLUS LAMIVUDINE PLUS ZIDOVUDINE; ASPARTATE AMINOTRANSFERASE; ETHAMBUTOL; ISONIAZID; PYRAZINAMIDE; RIFAMPICIN; VIRUS RNA;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADULT; ANEMIA; ARTICLE; ASCITES; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CD4 LYMPHOCYTE COUNT; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG ERUPTION; DRUG SAFETY; EVENT FREE SURVIVAL; FEMALE; HEART ARRHYTHMIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTED PATIENT; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERTENSION; HYPOTENSION; LOBAR PNEUMONIA; LONGITUDINAL STUDY; LUNG TUBERCULOSIS; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MORTALITY; MOTOR DYSFUNCTION; MYCOBACTERIUM TUBERCULOSIS; NEUTROPENIA; OPEN STUDY; OUTCOME ASSESSMENT; PEPTIC ULCER; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SIDE EFFECT; SPUTUM SMEAR; THERAPY DELAY; THROMBOCYTOPENIA; TREATMENT DURATION; UGANDA; VIRUS INHIBITION; VIRUS LOAD;

EID: 80052221998     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1093/infdis/jir503     Document Type: Article

References (30)

1. Lawn S.D., Kranzer K., Edwards D.J., McNally M., Bekker L.G., Wood R. Tuberculosis during the first year of antiretroviral therapy in a South African cohort using an intensive pretreatment screening strategy. AIDS 2010; 24:1323-8.
2. Whalen C.C., Okwera A., Johnson J., et al. Predictors of survival in human immunodeficiency virus-infected patients with pulmonary tuberculosis. Am J Respir Crit Care Med 1996; 153:1977-81.
3. Wiktor S.Z., Sassan-Morokro M., Grant A.D., et al. Efficacy of trimethoprim- Sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-sulphamethoxazole prophylaxis to decrease morbidity and mortality in HIV-1-infected patients with tuberculosis in Abidjan, Cote d'Ivoire: a randomised controlled trial. Lancet 1999; 353:1469-75.
4. Whalen C., Horsburgh C.R., Hom D., Lahart C., Simberkoff M., Ellner J. Accelerated course of human immunodeficiency virus infection after tuberculosis. Am J Respir Crit Care Med 1995; 151:129-35.
5. Whalen C.C., Nsubuga P., Okwera A., et al. Impact of pulmonary tuberculosis on survival of HIV-infected adults: a prospective epidemiologic study in Uganda. AIDS 2000; 14:1219-28.
6. Lopez-Gatell H., Cole S.R., Hessol N.A., et al. Effect of tuberculosis on the survival of women infected with human immunodeficiency virus. Am J Epidemiol 2007; 165:1134-142. (Pubitemid 47233709)
7. Lopez-Gatell H., Cole S.R., Margolick J.B., et al. Effect of tuberculosis on the survival of HIV-infected men in a country with low tuberculosis incidence. AIDS 2008; 22:1869-73.
8. World Health Organization. Antiretroviral therapy for HIV infection in adults and adolescents: recommendations for a public health approach. Austria: World Health Organization, 2010:45-6.
9. Abdool Karim S.S., Naidoo K., Grobler A., et al. Timing of initiation of antiretroviral drugs during tuberculosis therapy. N Engl J Med 2010; 362:697-706.
10. Blanc F.X., Sok T., Laurelliard D., et al. Significant enhancement in survival with early (2 weeks) vs. late (8weeks) of highly active antiretroviral treatment (HAART) in severely immunosuppressed HIV-infected adults with newly diagnosed tuberculosis. Vienna: International AIDS Society, 2010:284-5.
11. Dean G.L., Edwards S.G., Ives N.J., et al. Treatment of tuberculosis in HIV-infected persons in the era of highly active antiretroviral therapy. AIDS 2002; 16:75-83. (Pubitemid 34062184)
12. Girardi E., Palmieri F., Cingolani A., et al. Changing clinical presentation and survival in HIV-associated tuberculosis after highly active antiretroviral therapy. J Acquir Immune Defic Syndr 2001; 26:326-31. (Pubitemid 32435996)
13. Leonard M.K., Larsen N., Drechsler H., et al. Increased survival of persons with tuberculosis and human immunodeficiency virus infection, 1991-2000. Clin Infect Dis 2002; 34:1002-7.
14. El-Sadr W.M., Lundgren J.D., Neaton J.D., et al. CD4+ count-guided interruption of antiretroviral treatment. N Engl J Med 2006; 355:2283-296. (Pubitemid 44837777)
15. Uganda Ministry of Health. Uganda national policy guidelines for HIV voluntary counselling and testing. Kampala, Uganda: Ministry of Health, 2003.
16. Badri M., Bekker L-G, Orrell C., Pitt J., Ciliers F., Wood R. Initiating highly active antiretroviral therapy in sub-Saharan Africa: an assessment of the revised World Health Organization scaling-Saharan Africa: an assessment of the revised World Health Organization scalingUp guidelines. AIDS 2004; 18:1159-68. (Pubitemid 38738515)
17. Velasco M., Castilla V., Sanz J., et al. Effect of simultaneous use of highly active antiretroviral therapy on survival of HIV patients with tuberculosis. J Acquir Immune Defic Syndr 2009; 50:148-52.
18. Boulle A., Van C.G., Cohen K., et al. Outcomes of nevirapine- and efavirenz-based antiretroviral therapy when coadministered with rifampicin-based antitubercular therapy. JAMA 2008; 300:530-9.
19. Toossi Z. Virological and immunological impact of tuberculosis on human immunodeficiency virus type 1 disease. J Infect Dis 2003; 188:1146-55. (Pubitemid 37338979)
20. Wallis R.S., Nsubuga P., Whalen C., et al. Pentoxifylline therapy in human immunodeficiency virus-seropositive persons with tuberculosis: a randomized, controlled trial. J Infect Dis 1996:727-33. (Pubitemid 26325887)
21. Wallis R.S., Kyambadde P., Johnson J.L., et al. A study of the safety, immunology, virology, and microbiology of adjunctive etanercept in HIV-1-1-associated tuberculosis. AIDS 2004; 18:257-64. (Pubitemid 38253448)
22. Mayanja-Kizza H., Jones-Lopez E., Okwera A., et al. Immunoadjuvant prednisolone therapy for HIV-associated tuberculosis: a phase 2 clinical trial in Uganda. J Infect Dis 2005; 191:856-65. (Pubitemid 40349799)
23. Gulick R.M., Ribaudo H.J., Shikuma C.M., et al. Triple-nucleoside regimens versus efavirenz-containing regimens for the initial treatment of HIV-1 infection. N Engl J Med 2004; 350:1850-61.
24. Srikantiah P., Walusimbi M.N., Kayanja H.K., et al. Early virological response of zidovudine/lamivudine/abacavir for patients co-infected with HIV and tuberculosis in Uganda. AIDS 2007; 21:1972-4.
25. Moses A., Nelson J., Bagby G.C. Jr. The influence of human immunodeficiency virus-1 on hematopoiesis. Blood 1998; 91:1479-95.
26. Volberding P.A., Baker K.R., Levine A.M. Human immunodeficiency virus hematology. Hematology Am Soc Hematol Educ Program 2003:294-313.
27. Levine A.M., Karim R., Mack W., et al. Neutropenia in human immunodeficiency virus infection: Data from the women's interagency HIV study. Arch Intern Med 2006; 166:405-10.
28. Severe P., Juste M.A., Ambroise A., et al. Early versus standard antiretroviral therapy for HIV-infected adults in Haiti. N Engl J Med 2010; 363:257-65.
29. Sterne J.A., May M., Costagliola D., et al. Timing of initiation of antiretroviral therapy in AIDS-free HIV-1-infected patients: A collaborative analysis of 18 HIV cohort studies. Lancet 2009; 373: 1352-63.
30. Kitahata M.M., Gange S.J., Abraham A.G., et al. Effect of early versus deferred antiretroviral therapy for HIV on survival. N Engl J Med 2009; 360:1815-26.